Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new investors
Current investors ARCH Venture Partners, Forbion Ventures, ND Capital, and others also participated
AIRNA expected to file clinical trial application for Alpha-1 antitrypsin deficiency (AATD) RNA editing product candidate (AIR-001) with potential best-in-class profile in 2H 2025
CAMBRIDGE, MA, USA & TÜBINGEN, Germany I April 01, 2025 I